King Pharmaceuticals®, Inc. Announces the Discontinuation of Florinef (fludrocortisone acetate tablets, USP)

San Francisco – King Pharmaceuticals announced the discontinuation of Florinef (fludrocortisone acetate tablets, USP) on June 7, 2007. Florinef Acetate is indicated as a therapy in the treatment of adrenocortical insufficiency in Addison’s disease and for the treatment of salt-losing adrenogenital syndrome. To view the letter to the health care provider, please visit: http://www.fda.gov/cder/drug/shortages/florinef.pdf